Antiviral RNAi: Translating Science Towards Therapeutic Success
Identifieur interne : 000848 ( Istex/Corpus ); précédent : 000847; suivant : 000849Antiviral RNAi: Translating Science Towards Therapeutic Success
Auteurs : Priya S. Shah ; David V. SchafferSource :
- Pharmaceutical Research [ 0724-8741 ] ; 2011-12-01.
English descriptors
- KwdEn :
Abstract
ABSTRACT: Viruses continuously evolve to contend with an ever-changing environment that involves transmission between hosts and sometimes species, immune responses, and in some cases therapeutic interventions. Given the high mutation rate of viruses relative to the timescales of host evolution and drug development, novel drug classes that are readily screened and translated to the clinic are needed. RNA interference (RNAi)—a natural mechanism for specific degradation of target RNAs that is conserved from plants to invertebrates and vertebrates—can potentially be harnessed to yield therapies with extensive specificity, ease of design, and broad application. In this review, we discuss basic mechanisms of action and therapeutic applications of RNAi, including design considerations and areas for future development in the field.
Url:
DOI: 10.1007/s11095-011-0549-8
Links to Exploration step
ISTEX:D63B45FEC0E341566F631466A2B2D648A8FBF71ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral RNAi: Translating Science Towards Therapeutic Success</title><author><name sortKey="Shah, Priya S" sort="Shah, Priya S" uniqKey="Shah P" first="Priya S." last="Shah">Priya S. Shah</name><affiliation><mods:affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Schaffer, David V" sort="Schaffer, David V" uniqKey="Schaffer D" first="David V." last="Schaffer">David V. Schaffer</name><affiliation><mods:affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Bioengineering, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Helen Wills Neuroscience Institute, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: schaffer@berkeley.edu</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D63B45FEC0E341566F631466A2B2D648A8FBF71A</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/s11095-011-0549-8</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-X8GRXVMF-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000848</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000848</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antiviral RNAi: Translating Science Towards Therapeutic Success</title><author><name sortKey="Shah, Priya S" sort="Shah, Priya S" uniqKey="Shah P" first="Priya S." last="Shah">Priya S. Shah</name><affiliation><mods:affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Schaffer, David V" sort="Schaffer, David V" uniqKey="Schaffer D" first="David V." last="Schaffer">David V. Schaffer</name><affiliation><mods:affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Bioengineering, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Helen Wills Neuroscience Institute, University of California, 94720, Berkeley, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: schaffer@berkeley.edu</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmaceutical Research</title><title level="j" type="sub">An Official Journal of the American Association of Pharmaceutical Scientists</title><title level="j" type="abbrev">Pharm Res</title><idno type="ISSN">0724-8741</idno><idno type="eISSN">1573-904X</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2011-12-01">2011-12-01</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2966">2966</biblScope><biblScope unit="page" to="2982">2982</biblScope></imprint><idno type="ISSN">0724-8741</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0724-8741</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>RNA interference (RNAi)</term><term>antiviral</term><term>gene therapy</term><term>viral escape</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABSTRACT: Viruses continuously evolve to contend with an ever-changing environment that involves transmission between hosts and sometimes species, immune responses, and in some cases therapeutic interventions. Given the high mutation rate of viruses relative to the timescales of host evolution and drug development, novel drug classes that are readily screened and translated to the clinic are needed. RNA interference (RNAi)—a natural mechanism for specific degradation of target RNAs that is conserved from plants to invertebrates and vertebrates—can potentially be harnessed to yield therapies with extensive specificity, ease of design, and broad application. In this review, we discuss basic mechanisms of action and therapeutic applications of RNAi, including design considerations and areas for future development in the field.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Priya S. Shah</name><affiliations><json:string>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</json:string></affiliations></json:item><json:item><name>David V. Schaffer</name><affiliations><json:string>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</json:string><json:string>Department of Bioengineering, University of California, 94720, Berkeley, California, USA</json:string><json:string>Helen Wills Neuroscience Institute, University of California, 94720, Berkeley, California, USA</json:string><json:string>E-mail: schaffer@berkeley.edu</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>antiviral</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>gene therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>RNA interference (RNAi)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>viral escape</value></json:item></subject><articleId><json:string>549</json:string><json:string>s11095-011-0549-8</json:string></articleId><arkIstex>ark:/67375/VQC-X8GRXVMF-3</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>ReviewPaper</json:string></originalGenre><abstract>ABSTRACT: Viruses continuously evolve to contend with an ever-changing environment that involves transmission between hosts and sometimes species, immune responses, and in some cases therapeutic interventions. Given the high mutation rate of viruses relative to the timescales of host evolution and drug development, novel drug classes that are readily screened and translated to the clinic are needed. RNA interference (RNAi)—a natural mechanism for specific degradation of target RNAs that is conserved from plants to invertebrates and vertebrates—can potentially be harnessed to yield therapies with extensive specificity, ease of design, and broad application. In this review, we discuss basic mechanisms of action and therapeutic applications of RNAi, including design considerations and areas for future development in the field.</abstract><qualityIndicators><refBibsNative>false</refBibsNative><abstractWordCount>117</abstractWordCount><abstractCharCount>835</abstractCharCount><keywordCount>4</keywordCount><score>8.404</score><pdfWordCount>10882</pdfWordCount><pdfCharCount>73271</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>17</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize></qualityIndicators><title>Antiviral RNAi: Translating Science Towards Therapeutic Success</title><genre><json:string>review-article</json:string></genre><host><title>Pharmaceutical Research</title><language><json:string>unknown</json:string></language><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><issn><json:string>0724-8741</json:string></issn><eissn><json:string>1573-904X</json:string></eissn><journalId><json:string>11095</json:string></journalId><volume>28</volume><issue>12</issue><pages><first>2966</first><last>2982</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Biomedical Engineering</value></json:item><json:item><value>Medical Law</value></json:item><json:item><value>Biochemistry, general</value></json:item><json:item><value>Pharmacy</value></json:item><json:item><value>Pharmacology/Toxicology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-X8GRXVMF-3</json:string></ark><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1007/s11095-011-0549-8</json:string></doi><id>D63B45FEC0E341566F631466A2B2D648A8FBF71A</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-X8GRXVMF-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-X8GRXVMF-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-X8GRXVMF-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Antiviral RNAi: Translating Science Towards Therapeutic Success</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><availability><licence><p>Springer Science+Business Media, LLC, 2011</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2011-04-21</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Expert Review</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Antiviral RNAi: Translating Science Towards Therapeutic Success</title><author xml:id="author-0000"><persName><forename type="first">Priya</forename><surname>Shah</surname></persName><affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</affiliation></author><author xml:id="author-0001" corresp="yes"><persName><forename type="first">David</forename><surname>Schaffer</surname></persName><email>schaffer@berkeley.edu</email><affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</affiliation><affiliation>Department of Bioengineering, University of California, 94720, Berkeley, California, USA</affiliation><affiliation>Helen Wills Neuroscience Institute, University of California, 94720, Berkeley, California, USA</affiliation></author><idno type="istex">D63B45FEC0E341566F631466A2B2D648A8FBF71A</idno><idno type="ark">ark:/67375/VQC-X8GRXVMF-3</idno><idno type="DOI">10.1007/s11095-011-0549-8</idno><idno type="article-id">549</idno><idno type="article-id">s11095-011-0549-8</idno></analytic><monogr><title level="j">Pharmaceutical Research</title><title level="j" type="sub">An Official Journal of the American Association of Pharmaceutical Scientists</title><title level="j" type="abbrev">Pharm Res</title><idno type="pISSN">0724-8741</idno><idno type="eISSN">1573-904X</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">30</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2011-12-01"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2966">2966</biblScope><biblScope unit="page" to="2982">2982</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011-04-21</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>ABSTRACT: Viruses continuously evolve to contend with an ever-changing environment that involves transmission between hosts and sometimes species, immune responses, and in some cases therapeutic interventions. Given the high mutation rate of viruses relative to the timescales of host evolution and drug development, novel drug classes that are readily screened and translated to the clinic are needed. RNA interference (RNAi)—a natural mechanism for specific degradation of target RNAs that is conserved from plants to invertebrates and vertebrates—can potentially be harnessed to yield therapies with extensive specificity, ease of design, and broad application. In this review, we discuss basic mechanisms of action and therapeutic applications of RNAi, including design considerations and areas for future development in the field.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>KEY WORDS</head><item><term>antiviral</term></item><item><term>gene therapy</term></item><item><term>RNA interference (RNAi)</term></item><item><term>viral escape</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Biomedicine</head><item><term>Biomedical Engineering</term></item><item><term>Medical Law</term></item><item><term>Biochemistry, general</term></item><item><term>Pharmacy</term></item><item><term>Pharmacology/Toxicology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-04-21">Created</change><change when="2011-12-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-X8GRXVMF-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer US</PublisherName><PublisherLocation>Boston</PublisherLocation><PublisherURL>http://www.springer-ny.com</PublisherURL></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="NonStandardArchiveJournal" NumberingStyle="Unnumbered"><JournalID>11095</JournalID><JournalPrintISSN>0724-8741</JournalPrintISSN><JournalElectronicISSN>1573-904X</JournalElectronicISSN><JournalTitle>Pharmaceutical Research</JournalTitle><JournalSubTitle>An Official Journal of the American Association of Pharmaceutical Scientists</JournalSubTitle><JournalAbbreviatedTitle>Pharm Res</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Biomedicine</JournalSubject><JournalSubject Type="Secondary">Biomedical Engineering</JournalSubject><JournalSubject Type="Secondary">Medical Law</JournalSubject><JournalSubject Type="Secondary">Biochemistry, general</JournalSubject><JournalSubject Type="Secondary">Pharmacy</JournalSubject><JournalSubject Type="Secondary">Pharmacology/Toxicology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>28</VolumeIDStart><VolumeIDEnd>28</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>12</IssueIDStart><IssueIDEnd>12</IssueIDEnd><IssueArticleCount>30</IssueArticleCount><IssueHistory><OnlineDate><Year>2011</Year><Month>12</Month><Day>3</Day></OnlineDate><PrintDate><Year>2011</Year><Month>12</Month><Day>2</Day></PrintDate><CoverDate><Year>2011</Year><Month>12</Month></CoverDate><PricelistYear>2011</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName><CopyrightYear>2011</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s11095-011-0549-8" OutputMedium="All"><ArticleInfo ArticleType="ReviewPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>549</ArticleID><ArticleDOI>10.1007/s11095-011-0549-8</ArticleDOI><ArticleSequenceNumber>2</ArticleSequenceNumber><ArticleTitle Language="En">Antiviral RNAi: Translating Science Towards Therapeutic Success</ArticleTitle><ArticleCategory>Expert Review</ArticleCategory><ArticleFirstPage>2966</ArticleFirstPage><ArticleLastPage>2982</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2011</Year><Month>7</Month><Day>25</Day></RegistrationDate><Received><Year>2011</Year><Month>4</Month><Day>21</Day></Received><Accepted><Year>2011</Year><Month>7</Month><Day>25</Day></Accepted><OnlineDate><Year>2011</Year><Month>8</Month><Day>9</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName><CopyrightYear>2011</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Priya</GivenName><GivenName>S.</GivenName><FamilyName>Shah</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1 Aff2 Aff3" CorrespondingAffiliationID="Aff3"><AuthorName DisplayOrder="Western"><GivenName>David</GivenName><GivenName>V.</GivenName><FamilyName>Schaffer</FamilyName></AuthorName><Contact><Email>schaffer@berkeley.edu</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Department of Chemical and Biolmolecular Engineering</OrgDivision><OrgName>University of California</OrgName><OrgAddress><City>Berkeley</City><State>California</State><Postcode>94720</Postcode><Country Code="US">USA</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Department of Bioengineering</OrgDivision><OrgName>University of California</OrgName><OrgAddress><City>Berkeley</City><State>California</State><Postcode>94720</Postcode><Country Code="US">USA</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Helen Wills Neuroscience Institute</OrgDivision><OrgName>University of California</OrgName><OrgAddress><City>Berkeley</City><State>California</State><Postcode>94720</Postcode><Country Code="US">USA</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>ABSTRACT</Heading><Para>Viruses continuously evolve to contend with an ever-changing environment that involves transmission between hosts and sometimes species, immune responses, and in some cases therapeutic interventions. Given the high mutation rate of viruses relative to the timescales of host evolution and drug development, novel drug classes that are readily screened and translated to the clinic are needed. RNA interference (RNAi)—a natural mechanism for specific degradation of target RNAs that is conserved from plants to invertebrates and vertebrates—can potentially be harnessed to yield therapies with extensive specificity, ease of design, and broad application. In this review, we discuss basic mechanisms of action and therapeutic applications of RNAi, including design considerations and areas for future development in the field.</Para></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>KEY WORDS</Heading><Keyword>antiviral</Keyword><Keyword>gene therapy</Keyword><Keyword>RNA interference (RNAi)</Keyword><Keyword>viral escape</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Antiviral RNAi: Translating Science Towards Therapeutic Success</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Antiviral RNAi: Translating Science Towards Therapeutic Success</title></titleInfo><name type="personal"><namePart type="given">Priya</namePart><namePart type="given">S.</namePart><namePart type="family">Shah</namePart><affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">David</namePart><namePart type="given">V.</namePart><namePart type="family">Schaffer</namePart><affiliation>Department of Chemical and Biolmolecular Engineering, University of California, 94720, Berkeley, California, USA</affiliation><affiliation>Department of Bioengineering, University of California, 94720, Berkeley, California, USA</affiliation><affiliation>Helen Wills Neuroscience Institute, University of California, 94720, Berkeley, California, USA</affiliation><affiliation>E-mail: schaffer@berkeley.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="ReviewPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Springer US; http://www.springer-ny.com</publisher><place><placeTerm type="text">Boston</placeTerm></place><dateCreated encoding="w3cdtf">2011-04-21</dateCreated><dateIssued encoding="w3cdtf">2011-12-01</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">ABSTRACT: Viruses continuously evolve to contend with an ever-changing environment that involves transmission between hosts and sometimes species, immune responses, and in some cases therapeutic interventions. Given the high mutation rate of viruses relative to the timescales of host evolution and drug development, novel drug classes that are readily screened and translated to the clinic are needed. RNA interference (RNAi)—a natural mechanism for specific degradation of target RNAs that is conserved from plants to invertebrates and vertebrates—can potentially be harnessed to yield therapies with extensive specificity, ease of design, and broad application. In this review, we discuss basic mechanisms of action and therapeutic applications of RNAi, including design considerations and areas for future development in the field.</abstract><note>Expert Review</note><subject lang="en"><genre>KEY WORDS</genre><topic>antiviral</topic><topic>gene therapy</topic><topic>RNA interference (RNAi)</topic><topic>viral escape</topic></subject><relatedItem type="host"><titleInfo><title>Pharmaceutical Research</title><subTitle>An Official Journal of the American Association of Pharmaceutical Scientists</subTitle></titleInfo><titleInfo type="abbreviated"><title>Pharm Res</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2011-12-03</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><subject><genre>Biomedicine</genre><topic>Biomedical Engineering</topic><topic>Medical Law</topic><topic>Biochemistry, general</topic><topic>Pharmacy</topic><topic>Pharmacology/Toxicology</topic></subject><identifier type="ISSN">0724-8741</identifier><identifier type="eISSN">1573-904X</identifier><identifier type="JournalID">11095</identifier><identifier type="IssueArticleCount">30</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>2011</date><detail type="volume"><number>28</number><caption>vol.</caption></detail><detail type="issue"><number>12</number><caption>no.</caption></detail><extent unit="pages"><start>2966</start><end>2982</end></extent></part><recordInfo><recordOrigin>Springer Science+Business Media, LLC, 2011</recordOrigin></recordInfo></relatedItem><identifier type="istex">D63B45FEC0E341566F631466A2B2D648A8FBF71A</identifier><identifier type="ark">ark:/67375/VQC-X8GRXVMF-3</identifier><identifier type="DOI">10.1007/s11095-011-0549-8</identifier><identifier type="ArticleID">549</identifier><identifier type="ArticleID">s11095-011-0549-8</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer Science+Business Media, LLC, 2011</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Springer Science+Business Media, LLC, 2011</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-X8GRXVMF-3/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000848 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000848 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D63B45FEC0E341566F631466A2B2D648A8FBF71A
|texte= Antiviral RNAi: Translating Science Towards Therapeutic Success
}}
| This area was generated with Dilib version V0.6.33. |  |